

09 Jul 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: new AstraZeneca ADC lung cancer data seen as underwhelming; William Pao's aspirations at Pfizer; Scholar Rock's hopes for SMA asset; Biomarin's Roctavian launch; and Indian lighthouses deliver gains.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 July 2023, including: new [AstraZeneca PLC](#) ADC lung cancer data seen as underwhelming; William Pao's aspirations at [Pfizer Inc.](#); [Scholar Rock, LLC](#)'s hopes for SMA asset; [BioMarin Pharmaceutical Inc.](#)'s Roctavian launch; and Indian lighthouses deliver gains.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[AstraZeneca's Dato-DXd Falls Short Of Great Expectations In Lung Cancer Study](#)" - Scrip, 3 Jul, 2023.)

(Also see "[William Pao On Pfizer's 'Aspirational' Drug Development Goal, Seagen And More](#)" - Scrip, 5 Jul, 2023.)

(Also see "[Scholar Rock Looks To Augment Existing Therapies In Spinal Muscular Atrophy](#)" - Scrip, 3 Jul, 2023.)

(Also see "[Its Gene Therapy Roctavian Finally Approved With \\$2.9m Price, BioMarin Aims To Prove Doubters Wrong](#)" - Scrip, 30 Jun, 2023.)

(Also see "[Indian 'Lighthouses' Deliver Gains Amid Price Erosion, Rising Input Costs](#)" - Scrip, 3 Jul, 2023.)

[Click here to explore this interactive content online](#) ✨